Skip to main content
Top
Published in: Journal of Thrombosis and Thrombolysis 2/2008

01-04-2008

Soluble P-selectin and vascular endothelial growth factor in steady state sickle cell disease: relationship to genotype

Authors: A. D. Blann, J. S. Mohan, D. Bareford, G. Y. H. Lip

Published in: Journal of Thrombosis and Thrombolysis | Issue 2/2008

Login to get access

Abstract

Sickle cell disease (SCD) is characterised by abnormal coagulopathy and angiogenesis although their relationships in two common genotypes, homozygous (HbSS) SCD and sickle-haemoglobin C disease (HbSC), are unexplored. We measured markers of platelet activation (soluble P-selectin [sP-selectin]), fibrinolysis (D-dimer) and angiogenesis (vascular endothelial growth factor [VEGF]) in 27 HbSS patients, 37 HbSC patients and in 42 age and race matched subjects with normal haemoglobin (AA). sP-selectin (P = 0.025) and D-dimers (P < 0.001) were higher in HbSS than in HbSC but there was no difference in VEGF. In HbSC, sPselectin correlated with VEGF (P = 0.012) and D-dimers (P = 0.021). There were no significant correlations in health or in HbSS. Platelet and coagulation activation, but not angiogenic activity, is elevated in HbSS disease compared to the clinically milder HbSC genotype. The correlation between sP-selectin and VEGF in SCD and HbSC disease is consistent with the view that VEGF is released from platelets during in vivo activation.
Literature
1.
go back to reference Embury SH, Hebbel RP, Steinberg MH, Mohandas N (1994) Pathogenesis of vaso-occlusion. In: Embury SD, Hebbel RP, Mohandas N, Steinberg MH (eds) Sickle cell disease: basic principles and clinical practice. Raven Press, New York, pp 703–724 Embury SH, Hebbel RP, Steinberg MH, Mohandas N (1994) Pathogenesis of vaso-occlusion. In: Embury SD, Hebbel RP, Mohandas N, Steinberg MH (eds) Sickle cell disease: basic principles and clinical practice. Raven Press, New York, pp 703–724
2.
go back to reference Francis RB Jr (1991) Platelets, coagulation, and fibrinolysis in sickle cell disease: their possible role in vascular occlusion. Blood Coagul Fibrinolysis 2:341–353PubMedCrossRef Francis RB Jr (1991) Platelets, coagulation, and fibrinolysis in sickle cell disease: their possible role in vascular occlusion. Blood Coagul Fibrinolysis 2:341–353PubMedCrossRef
3.
go back to reference Stuart MJ, Setty BN (2001). Hemostatic alterations in sickle cell disease: relationships to disease pathophysiology. Pediatr Pathol Mol Med 20:27–46PubMedCrossRef Stuart MJ, Setty BN (2001). Hemostatic alterations in sickle cell disease: relationships to disease pathophysiology. Pediatr Pathol Mol Med 20:27–46PubMedCrossRef
4.
go back to reference Ataga KI, Orringer EP (2003) Hypercoagulability in sickle cell disease: a curious paradox. Am J Med 115:721–728PubMedCrossRef Ataga KI, Orringer EP (2003) Hypercoagulability in sickle cell disease: a curious paradox. Am J Med 115:721–728PubMedCrossRef
5.
go back to reference Westerman MP, Green D, Gilman-Sachs A, Beaman K, Freels S, Boggio L, Allen S, Zuckerman L, Schlegel R, Williamson P (1999) Antiphospholipid antibodies, proteins C and S, and coagulation changes in sickle cell disease. J Lab Clin Med 134:352–362PubMedCrossRef Westerman MP, Green D, Gilman-Sachs A, Beaman K, Freels S, Boggio L, Allen S, Zuckerman L, Schlegel R, Williamson P (1999) Antiphospholipid antibodies, proteins C and S, and coagulation changes in sickle cell disease. J Lab Clin Med 134:352–362PubMedCrossRef
6.
go back to reference Tomer A, Harker LA, Kasey S, Eckman JR (2001) Thrombogenesis in sickle cell disease. J Lab Clin Med 137:398–407PubMedCrossRef Tomer A, Harker LA, Kasey S, Eckman JR (2001) Thrombogenesis in sickle cell disease. J Lab Clin Med 137:398–407PubMedCrossRef
7.
go back to reference Setty BN, Chen D, O’Neal P, Littrell JB, Grossman MH, Stuart MJ (1998) Eicosanoids in sickle cell disease: potential relevance of 12(S)-hydroxy-5,8,10,14-eicosatetraenoic acid to the pathophysiology of vaso-occlusion. J Lab Clin Med 131:344–353PubMedCrossRef Setty BN, Chen D, O’Neal P, Littrell JB, Grossman MH, Stuart MJ (1998) Eicosanoids in sickle cell disease: potential relevance of 12(S)-hydroxy-5,8,10,14-eicosatetraenoic acid to the pathophysiology of vaso-occlusion. J Lab Clin Med 131:344–353PubMedCrossRef
8.
go back to reference Blann AD, Marwah S, Serjeant G, Bareford D, Wright J (2003) Platelet activation and endothelial cell dysfunction in sickle cell disease is unrelated to reduced antioxidant capacity. Blood Coagul Fibrinolysis 14:255–259PubMedCrossRef Blann AD, Marwah S, Serjeant G, Bareford D, Wright J (2003) Platelet activation and endothelial cell dysfunction in sickle cell disease is unrelated to reduced antioxidant capacity. Blood Coagul Fibrinolysis 14:255–259PubMedCrossRef
9.
go back to reference Dvorak HF, Brown LF, Detmar M, Dvorak AM (1995) Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol 146:1029–1039PubMed Dvorak HF, Brown LF, Detmar M, Dvorak AM (1995) Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol 146:1029–1039PubMed
10.
go back to reference Solovey A, Gui L, Ramakrishnan S, Steinberg MH, Hebbel RP (1999) Sickle cell anemia as a possible state of enhanced anti-apoptotic tone: survival effect of vascular endothelial growth factor on circulating and unanchored endothelial cells. Blood 93:3824–3830PubMed Solovey A, Gui L, Ramakrishnan S, Steinberg MH, Hebbel RP (1999) Sickle cell anemia as a possible state of enhanced anti-apoptotic tone: survival effect of vascular endothelial growth factor on circulating and unanchored endothelial cells. Blood 93:3824–3830PubMed
11.
go back to reference Marti HH, Risau W (1999) Angiogenesis in ischemic disease. Thromb Haemost 82(Suppl 1):44–52PubMed Marti HH, Risau W (1999) Angiogenesis in ischemic disease. Thromb Haemost 82(Suppl 1):44–52PubMed
12.
go back to reference Mohle R, Green D, Moore MA, Nachman RL, Rafii S (1997) Constitutive production and thrombin-induced release of vascular endothelial growth factor by human megakaryocytes and platelets. Proc Natl Acad Sci U S A 94:663–668PubMedCrossRef Mohle R, Green D, Moore MA, Nachman RL, Rafii S (1997) Constitutive production and thrombin-induced release of vascular endothelial growth factor by human megakaryocytes and platelets. Proc Natl Acad Sci U S A 94:663–668PubMedCrossRef
13.
go back to reference Banks RE, Forbes MA, Kinsey SE, Stanley A, Ingham E, Walters C, Selby PJ (1998) Release of the angiogenic cytokine vascular endothelial growth factor (VEGF) from platelets: significance for VEGF measurements and cancer biology. Br J Cancer 77:956–964PubMed Banks RE, Forbes MA, Kinsey SE, Stanley A, Ingham E, Walters C, Selby PJ (1998) Release of the angiogenic cytokine vascular endothelial growth factor (VEGF) from platelets: significance for VEGF measurements and cancer biology. Br J Cancer 77:956–964PubMed
14.
go back to reference Ballas SK, Lewis CN, Noone AM, Krasnow SH, Kamarulzaman E, Burka ER (1982) Clinical, hematological, and biochemical features of Hb SC disease. Am J Hematol 13:37–51PubMedCrossRef Ballas SK, Lewis CN, Noone AM, Krasnow SH, Kamarulzaman E, Burka ER (1982) Clinical, hematological, and biochemical features of Hb SC disease. Am J Hematol 13:37–51PubMedCrossRef
15.
go back to reference Hagger D, Wolff S, Owen J, Samson D (1995) Changes in coagulation and fibrinolysis in patients with sickle cell disease compared with healthy black controls. Blood Coagul Fibrinolysis 6:93–99PubMedCrossRef Hagger D, Wolff S, Owen J, Samson D (1995) Changes in coagulation and fibrinolysis in patients with sickle cell disease compared with healthy black controls. Blood Coagul Fibrinolysis 6:93–99PubMedCrossRef
16.
go back to reference Singhal A, Doherty JF, Raynes JG, McAdam KPWJ, Thomas PW, Serjeant BE, Serjeant GR (1993) Is there an acute phase response in steady-state sickle cell disease? Lancet 341:651–653PubMedCrossRef Singhal A, Doherty JF, Raynes JG, McAdam KPWJ, Thomas PW, Serjeant BE, Serjeant GR (1993) Is there an acute phase response in steady-state sickle cell disease? Lancet 341:651–653PubMedCrossRef
17.
go back to reference Blann AD, Lip GYH, Beevers DG, McCollum CN (1997) Soluble P-selectin in atherosclerosis: a comparison with endothelial cell and platelet markers. Thromb Haemostas 78:1077–1080 Blann AD, Lip GYH, Beevers DG, McCollum CN (1997) Soluble P-selectin in atherosclerosis: a comparison with endothelial cell and platelet markers. Thromb Haemostas 78:1077–1080
18.
go back to reference Fijnheer R, Frijns CJ, Korteweg J et al (1997). The origin of P-selectin in atherosclerosis: a comparison with endothelial cell and platelet markers. Thromb Haemostas 77:1081–1085 Fijnheer R, Frijns CJ, Korteweg J et al (1997). The origin of P-selectin in atherosclerosis: a comparison with endothelial cell and platelet markers. Thromb Haemostas 77:1081–1085
19.
go back to reference Verheul HM, Hoekman K, Luykx-de Bakker S, Eekman CA, Folman CC, Broxterman HJ, Pinedo HM (1997) Platelet: transporter of vascular endothelial growth factor. Clin Cancer Res 3:2187–2190PubMed Verheul HM, Hoekman K, Luykx-de Bakker S, Eekman CA, Folman CC, Broxterman HJ, Pinedo HM (1997) Platelet: transporter of vascular endothelial growth factor. Clin Cancer Res 3:2187–2190PubMed
20.
go back to reference Vermeulen PB, Salven P, Benoy I, Gasparini G, Dirix LY (1999) Blood platelets and serum VEGF in cancer patients. Br J Cancer 79:370–373PubMedCrossRef Vermeulen PB, Salven P, Benoy I, Gasparini G, Dirix LY (1999) Blood platelets and serum VEGF in cancer patients. Br J Cancer 79:370–373PubMedCrossRef
21.
go back to reference Zachary I (2001). Signaling mechanisms mediating vascular protective actions of vascular endothelial growth factor. Am J Physiol Cell Physiol 280:C1375–C1386PubMed Zachary I (2001). Signaling mechanisms mediating vascular protective actions of vascular endothelial growth factor. Am J Physiol Cell Physiol 280:C1375–C1386PubMed
22.
go back to reference Zachary I, Mathur A, Yla-Herttuala S, Martin J (2000) Vascular protection: a novel nonangiogenic cardiovascular role for vascular endothelial growth factor. Arterioscler Thromb Vasc Biol. 20:1512–1520PubMed Zachary I, Mathur A, Yla-Herttuala S, Martin J (2000) Vascular protection: a novel nonangiogenic cardiovascular role for vascular endothelial growth factor. Arterioscler Thromb Vasc Biol. 20:1512–1520PubMed
23.
go back to reference Minchenko A, Bauer T, Salceda S, Caro J (1994) Hypoxic stimulation of vascular endothelial growth factor expression in vitro and in vivo. Lab Invest 71:374–379PubMed Minchenko A, Bauer T, Salceda S, Caro J (1994) Hypoxic stimulation of vascular endothelial growth factor expression in vitro and in vivo. Lab Invest 71:374–379PubMed
24.
go back to reference Shweiki D, Itin A, Soffer D, Keshet E (1992) Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 359:843–845PubMedCrossRef Shweiki D, Itin A, Soffer D, Keshet E (1992) Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 359:843–845PubMedCrossRef
25.
go back to reference Salgado R, Vermeulen PB, Benoy I, Weytjens R, Huget P, Van Marck E, Dirix LY (1999) Platelet number and interleukin-6 correlate with VEGF but not with bFGF serum levels of advanced cancer patients. Br J Cancer 80:892–897PubMedCrossRef Salgado R, Vermeulen PB, Benoy I, Weytjens R, Huget P, Van Marck E, Dirix LY (1999) Platelet number and interleukin-6 correlate with VEGF but not with bFGF serum levels of advanced cancer patients. Br J Cancer 80:892–897PubMedCrossRef
26.
go back to reference Bourantas KL, Dalekos GN, Makis A, Chaidos A, Tsiara S, Mavridis A (1998) Acute phase proteins and interleukins in steady state sickle cell disease. Eur J Haematol 61:49–54PubMedCrossRef Bourantas KL, Dalekos GN, Makis A, Chaidos A, Tsiara S, Mavridis A (1998) Acute phase proteins and interleukins in steady state sickle cell disease. Eur J Haematol 61:49–54PubMedCrossRef
Metadata
Title
Soluble P-selectin and vascular endothelial growth factor in steady state sickle cell disease: relationship to genotype
Authors
A. D. Blann
J. S. Mohan
D. Bareford
G. Y. H. Lip
Publication date
01-04-2008
Publisher
Springer US
Published in
Journal of Thrombosis and Thrombolysis / Issue 2/2008
Print ISSN: 0929-5305
Electronic ISSN: 1573-742X
DOI
https://doi.org/10.1007/s11239-007-0177-7

Other articles of this Issue 2/2008

Journal of Thrombosis and Thrombolysis 2/2008 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.